Note on source materials
- The materials provided contain mixed metadata (a short title referencing stormwater reporting and an unrelated bill short-title line) but the operative bill text included in full is Senate Bill No. 1609 (Massachusetts), an Act concerning the regulation of kratom. This summary therefore focuses on the kratom-regulation text contained in the filing (S.D. 806 / Sen. Jacob R. Oliveira).
Summary — purpose and intent
- The bill creates a new Chapter 94J in the Massachusetts General Laws to regulate the manufacture, sale, distribution, registration, and labeling of kratom (Mitragyna speciosa) and kratom-containing products. The intent is to protect public health by limiting harmful product forms and ingredients, requiring safety and manufacturing certifications, and establishing a registration and review regime.
Key definitions (selected)
- Kratom: Mitragyna speciosa or any part of the plant.
- Kratom product: Foods, dietary supplements, beverages, capsules, powders, etc., intended for human consumption that contain kratom leaf or extracts.
- Kratom extract: Extracts of kratom leaf intended for ingestion (with limits on residual solvents).
- Attractive to children: Packaging/shape that resembles candy, cartoons, animals, or widely recognized branded foods.
- Independent testing laboratory: ISO/IEC 17025–accredited lab.
- Synthesized material: Alkaloids or derivatives created by chemical or biosynthetic synthesis rather than traditional extraction.
Key provisions and restrictions
- 7-hydroxymitragynine limit: Kratom products may not contain more than 2% 7‑hydroxymitragynine of the alkaloid fraction.
- Prohibited adulterants: Products adulterated with non-kratom poisonous ingredients, controlled substances, dangerous psychoactive compounds (e.g., synthetic cannabinoids, synthetic cathinones), or compounds that significantly change safety profiles are banned.
- Drug‑interaction risk: Products mixed with compounds known to inhibit major CYP enzymes (CYP3A4/CYP2D6) are considered adulterated unless safety is scientifically validated and specifically permitted.
- Prohibited forms/uses: Combustible (smoking), vaporization, and injectable kratom products are prohibited.
- Child‑appealing products: Products that are “attractive to children” are prohibited.
- Synthesized/altered alkaloids: Use of synthesized materials or alkaloids artificially manipulated to increase potency is banned unless safety data support it.
- Residual solvents: Kratom extracts must meet residual solvent limits consistent with U.S. Pharmacopeia standards (USP <467> reference).
Registration, testing, and manufacturing requirements
- Annual registration: The party placing a product into commerce must register annually and pay fees covering administrative costs.
- Expert review fees: Additional fees may be charged to retain experts to review safety data submitted by registrants.
- Processor certifications: Registrants/processors must provide sworn certifications including compliance with CGMP comparable to 21 CFR 111 and a reasonable basis that the product is safe for labeled use.
- Testing: Independent laboratory testing is required (ISO/IEC 17025 accreditation referenced).
Who is affected
- Kratom product manufacturers, processors, distributors, retailers, kratom food service establishments, and independent testing labs. Consumers may see changes in product availability, labeling, and formulation.
Potential impacts
- Public health: Aims to reduce consumer exposure to adulterated or high‑potency kratom products and to prevent child‑appealing formulations.
- Industry compliance: Likely increased costs for testing, GMP compliance, registration fees, and reformulation; possible removal of certain product types from market (vape, injection, child‑appealing products).
- Enforcement/administration: New workload for the Department of Agricultural Resources (named “Department” in the bill) to administer registrations, review safety data, and enforce prohibitions.
Procedural/timeline notes (from provided actions)
- Bill filed 1/14/2025 (Senate Docket No. 806). Provided legislative action entries show committee referrals and scheduled hearings; some entries indicate passage in the Senate and transmission to the House/Assembly. The provided timeline entries contain repeated and sometimes conflicting items — verify current status with the official Massachusetts legislative website for the latest actions and amendments.
Limitations
- The provided bill text is truncated in parts. This summary reflects the language and provisions present in the submitted excerpts; readers should consult the full, official bill text for complete requirements and any later amendments.
